Zynerba Pharmaceuticals

June 30, 2020

Zynerba fragile after pivotal failure

The implosion of Zygel’s fragile X study leaves its developer few places to turn.

March 05, 2020

Zynerba hopes to crack fragile X at last

The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.

February 24, 2020

First fragile X test is approved, and Zynerba could benefit

The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.

September 29, 2017

Dravet hit makes Zogenix another September biotech winner

August 08, 2017

GW approaches crunch time

March 15, 2016

Zynerba Pharmaceuticals

Zynerba fragile after pivotal failure

Zynerba hopes to crack fragile X at last

First fragile X test is approved, and Zynerba could benefit

Dravet hit makes Zogenix another September biotech winner

GW approaches crunch time

Investors get high on cannabinoid news

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

Evaluate Vantage COVID-19 Report

Editor's Picks

Esmo 2020 preview – late-breaking immunotherapy

Esmo 2020 preview – a kidney cancer showdown gets star billing

More biotechs test the third way to market

Abbott rides to the rescue with $5 Covid-19 test

Are the stars waning for Pfizer’s haemophilia A gene therapy?